Detecting distinct molecular and cytogenetic abnormalities has increased relevance in AML.       Add medintel@hcpconnects[x].com to your address book to ensure quick delivery     View this as a Web page       Diagnosing AML and determining prognosis are critical       Acute myeloid leukemia (AML) is confirmed by bone marrow biopsy using morphologic, cytochemical, immunophenotypic, and cytogenetic/‌molecular analysis1       AML evolves rapidly because of its polyclonal and heterogeneous features, contributing to the clinical challenges of this disease2         • As an indicator of prognosis, cytogenetic and molecular mutation testing are recommended by the National Comprehensive Cancer Network® (NCCN®) at diagnosis1         Common molecular genetic mutations in AML (≥10%)3             Molecular genetic testing may be an important factor that can be utilized to facilitate clinical decision-making1       References: 1. Referenced with permission from the NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines®) for Acute Myeloid Leukemia V.2.2016. © National Comprehensive Cancer Network, Inc 2016. All rights reserved. Accessed June 29, 2016. To view the most recent and complete version of the guideline, go online to N‌CCN.o‌rg. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, NCCN GUIDELINES®, and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc. 2. Ferrara F, Schiffer CA. Acute myeloid leukaemia in adults. Lancet. 2013;381(9865):484-495. 3. Patel JP, Gönen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;366(12):1079-1089.       This is a sponsored message from DMD on behalf of Novartis Pharmaceuticals Corporation. DMD provides sponsored health care–related messages from trusted third parties. This material is intended specifically and exclusively for US health care professionals. You are receiving this email because you have subscribed and agreed to receive information from the DMD email list. If you prefer not to receive further information from DMD, please click here and confirm your request.       DMD 1‌0255 W. H‌iggins R‌oad, S‌uite 2‌80 R‌osemont, I‌L 6‌0018 DMD Privacy Policy         Novartis Pharmaceuticals Corporation O‌ne H‌ealth P‌laza E‌ast H‌anover, N‌ew J‌ersey 0‌7936-1‌080      © 2016 Novartis     8‌/16   MLA-1142755